Gabapentin is prescribed off-label at a rate that substantially exceeds its two FDA-approved indications. Estimates suggest off-label use accounts for 83–95% of all gabapentin prescriptions in the United States. The evidence base supporting this practice is uneven — robust in some areas, speculative in others.
Indication 1: Peripheral Neuropathy & Diabetic Nerve Pain
Peripheral neuropathic pain — the searing, electric, or burning dysesthesia that accompanies conditions such as diabetic peripheral neuropathy (DPN), chemotherapy-induced peripheral neuropathy (CIPN), and HIV-associated neuropathy — sits at the intersection of gabapentin's mechanism and its clinical utility. Voltage-gated calcium channel α2δ subunit upregulation has been documented in dorsal root ganglia following metabolic nerve injury, creating the precise molecular environment in which gabapentin's binding activity should, theoretically, matter.
Clinical data bear this out — to a point. The landmark Backonja et al. (1998) trial, published in JAMA, demonstrated that gabapentin at 3,600 mg/day produced statistically significant reduction in pain scores for DPN compared to placebo (mean pain score 6.4 at baseline reduced to 3.9 at endpoint, versus 5.1 in the placebo group). The number needed to treat (NNT) for ≥50% pain reduction in DPN is approximately 5.9 — meaning roughly 1 in 6 patients achieves substantial relief beyond placebo. Useful, but not uniformly effective.
For CIPN, the picture is considerably less encouraging. A 2013 Cochrane meta-analysis examining gabapentin and pregabalin for CIPN found insufficient evidence to recommend routine use, noting significant methodological heterogeneity across included trials and a high risk of publication bias. The distinction matters clinically: DPN and CIPN are not interchangeable models of peripheral neuropathy, and extrapolating DPN efficacy data to CIPN patients represents a meaningful clinical error.
Comparative Outcome Metrics by Indication
NNT = number needed to treat for ≥50% pain reduction vs. placebo. Lower NNT = greater efficacy. Bar width represents relative evidence strength.
Indication 2: Generalized Anxiety Disorder
The off-label use of gabapentin for anxiety disorders — particularly GAD and social anxiety disorder — grew significantly in the 2000s, coinciding with both prescribing concerns around benzodiazepines and Parke-Davis's eventually-litigated off-label promotion. The mechanistic rationale has some plausibility: calcium channel modulation in the basolateral amygdala and prefrontal cortex may dampen fear-conditioning circuits, and GABA-adjacent effects on inhibitory neurotransmission remain possible through indirect mechanisms despite gabapentin's non-GABA-ergic primary pathway.
What does the evidence actually show? A 2011 systematic review in Psychopharmacology Bulletin identified seven randomized controlled trials evaluating gabapentin for anxiety-spectrum disorders. Pooled results suggested modest efficacy over placebo for GAD (standardized mean difference ≈ −0.36), but with significant caveats: trial durations were short (4–8 weeks), sample sizes were small (median n = 68), and outcomes heterogeneity was substantial. None of these trials were adequately powered to detect safety signals at the individual patient level.
The clinical community remains divided. Some clinicians find gabapentin a useful adjunct in patients who cannot tolerate SSRIs or for whom benzodiazepines carry unacceptable risk — particularly older adults with comorbid pain syndromes, where a single agent addressing both symptoms has obvious appeal. Others argue the evidence base is too weak to justify scheduling a controlled substance for a non-approved indication when FDA-approved alternatives exist. Both positions are defensible. What is not defensible is prescribing without explicit discussion of the off-label nature of the treatment.
Indication 3: Restless Leg Syndrome
Restless leg syndrome (RLS) — characterized by an irresistible urge to move the legs, typically worse at rest and in the evening — has an established pharmacological lineage including dopamine agonists (pramipexole, ropinirole) and, notably, gabapentin enacarbil (Horizant®), an FDA-approved extended-release prodrug of gabapentin specifically indicated for moderate-to-severe primary RLS. This approval has generated a reasonable — though imprecise — clinical inference that immediate-release gabapentin should be similarly effective for RLS.
The distinction matters pharmacokinetically. Gabapentin enacarbil is a transported prodrug that bypasses the saturable intestinal amino acid transporter, achieving more predictable and dose-proportional absorption than conventional gabapentin. Its pharmacokinetic profile is meaningfully different. That said, observational data and smaller RCTs do support efficacy of standard gabapentin in RLS, with NNT estimates in the 6–8 range and particular benefit reported for the sensory component (the dysesthesia) over the motor component (periodic limb movements).
Dosing in RLS typically follows a once-nightly or twice-daily pattern (300–1,200 mg total daily dose), administered 1–2 hours before anticipated symptom onset. This timing-specific approach leverages gabapentin's Tmax of 2–4 hours to achieve peak plasma levels during the RLS symptom window, a nuance that is frequently overlooked in general prescribing practice.
Prescribing Safety: Schedule V Classification and Evolving Regulation
Gabapentin was not originally a federally scheduled substance. The DEA's 2019 review and subsequent state-level scheduling actions (Kentucky was first in 2017, followed by Michigan, Tennessee, Virginia, and others) reflect growing concern about its misuse potential — particularly its role in enhancing the euphoric effects of opioids and its documented presence in polysubstance overdose deaths. As of 2025, approximately 12 U.S. states classify gabapentin as a Schedule V controlled substance.
This regulatory evolution has not altered gabapentin's clinical utility profile, but it has added prescription monitoring program (PMP) obligations in affected states and created prescribing hesitancy that — in some patient populations — may be causing undertreatment of legitimate neuropathic pain. The science of risk stratification here is evolving. NNPRC's ongoing surveillance work aims to generate population-level data to inform nuanced, evidence-based prescribing guidelines that neither overstate misuse risk nor minimize it.